Cascinu S, Latini L, Fedeli A, Giordani P, Antognoli S, Catalano G, Cellerino R
Clinica di Oncologia Medica, Università di Ancona, Italy.
Anticancer Res. 1995 Nov-Dec;15(6B):2781-3.
The activity of FEM regimen in metastatic gastric cancer patients was assessed in seventy-seven patients receiving, as palliative treatment, 5FU 600 mg/m2 i.v. on days 1, 8, 29, 36; epiADR 70 mg/m2 i.v. on days 1, 29; MIT-C 10 mg/m2 i.v. on days 1, 29. Cycles were repeated every 58 days. One patient achieved a complete response and 12 a partial response, resulting in an overall response rate of 16% (95% CI: 8% to 24%). Median remission duration was 6 months. Median survival time for all patients was 8 months. Side-effects were mild and principally in the form of leukopenia (three episodes grade III). Our results support the recent findings about the lack of effectiveness of this regimen. Although it is a safe and well tolerable chemotherapeutic combination, FEM regimen should not be recommended as routinary treatment for gastric cancer patients who are not eligible for clinical trials.
在77例转移性胃癌患者中评估了FEM方案的活性，这些患者接受姑息治疗，在第1、8、29、36天静脉注射5-氟尿嘧啶（5FU）600mg/m²，在第1、29天静脉注射表柔比星（epiADR）70mg/m²，在第1、29天静脉注射丝裂霉素C（MIT-C）10mg/m²。每58天重复一个周期。1例患者达到完全缓解，12例患者达到部分缓解，总缓解率为16%（95%置信区间：8%至24%）。中位缓解持续时间为6个月。所有患者的中位生存时间为8个月。副作用较轻，主要表现为白细胞减少（3例Ⅲ级）。我们的结果支持了近期关于该方案无效的研究结果。尽管FEM方案是一种安全且耐受性良好的化疗组合，但对于不符合临床试验条件的胃癌患者，不应推荐将其作为常规治疗方案。
